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this strategy is integrated, patient-centred care and prevention, of which a
key component is the preventive treatment of persons at high risk of
tuberculosis.
Latent TB infection (LTBI) is an asymptomatic state identified by a positive
tuberculin skin test (TST) or interferon-gamma release (IGRA) result
(indicating immunosensitization to Mycobacterium tuberculosis antigen) in
the absence of clinical and chest radiological evidence of TB disease. Per-
sons with LTBI have a 10% lifetime risk of developing active TB. The high
risk period for developing active TB is within the first few years after initial
infection. The risk of developing active disease is also heavily dependent on
the host immunological status.
Preventive therapy (PT) with isoniazid has an efficacy of 60-90% in reducing
the development of active disease. Isoniazid hepatotoxicity rates have been
reported as 0.1% to 1%. Thus LTBI screening should be targeted at selected
high risk groups for whom the benefit of PT would outweigh the risk of drug
toxicity; and in whom adherence to and completion of PT is likely to be high.
Routine PT for persons living with HIV and for childhood contacts below 5
years of age has been recommended by the World Health Organization
(WHO) for several years. In late 2014, WHO published Guidelines for high /
upper middle-income countries with TB incidence rate < 100 / 100,000
population. These Guidelines recommend the systematic screening and
treatment of LTBI in people living with HIV, adult and child contacts of
pulmonary TB cases, patients initiating anti-TNF treatment, patients
receiving dialysis, patients preparing for organ or haematologic transplan-
tation and patients with silicosis.
Singapore, an intermediate TB incidence country with mass BCG vaccination
at birth, has performed LTBI screening of close contacts of infectious
pulmonary TB cases for PT since 1998. Our experience with this TB control
strategy will be presented.SYMPOSIUM 24 (SP 24)
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EPIDEMIOLOGY: ASIA VS. EUROPE
Giuseppe Cornaglia *, Alda Bazaj. Department of Pathology and Diagnostics,
University of Verona, Italy
Multi-drug-resistant organisms (MDRO) are still on the surge in virtually all
geographical areas, in spite of curbing antibiotic consumptions and of the
partial success of containment campaigns.
Emergence of new resistance determinants, with special reference to beta-
lactamases, genetic association of different resistance mechanisms, and
spread of MDR clones all account for this enduring threat to Public Health.
Although antimicrobial resistance is generally very high, prevalence of
various MDRO is different between Europe and Asia, as for both absolute
figures and resistance determinants. A good example is given by the
prevalence of different types of carbapenemases, some of which had their
first description in either Continent.
It must be underlined that, in both Continents, ’Continental’ rates are
almost invariably mere artifacts, since inter-State variability can be surpris-
ingly high.SP 24-2
CONTROLLING VRE USING TECHNOLOGY
Dale Fisher. National University Hospital System (NUHS), Singapore
Vancomycin-resistant enterococci (VRE) emerged at our hospital in the mid-
2000s. Despite implementing targeted active surveillance in 2006 with strict
single room isolation and contact precautions for those identified, theprevalence of VRE continued to rise. Further interventions were introduced
in late-2012 / early-2013 to effectively create a VRE Bundle.
This bundle comprised a number of efforts including 2 specific technologic
innovations, hydrogen peroxide terminal cleaning and an automated
electronic alert system to identify known VRE carriers at the time of
admission. In addition manual cleaning audits were enhanced, precautions
signage modified, and the manual cleaning solution changed. A ‘breakpoint’
regression model was fitted to the monthly number of VRE cases from
January 2008 to January 2014 to evaluate potentially differing trends before
and after each intervention.
A total of 341 cases were reported over this 73 month period. Sixty-five
percent of cases were identified after 48 hours of hospitalization, suggesting
hospital transmission. Sixty-three percent of cases were clinical cultures,
22% were from contact tracing, and 15% from active surveillance. The best
estimate for the breakpoint corresponds to early February 2013 (95%
confidence interval, CI: August 2012dJune 2013), when the bundle was
implemented. The peak incidence was 9.2 cases per month (95% CI:
6.0d13.2) in March 2013 and reduced to 2.4 case per month (95%
CI:1.1d4.7) by January 2014.
Conclusions: The bundle of interventions was associated with a significant
change in the incidence of VRE at our hospital. Confidence intervals around
the breakpoint suggested that all elements of the bundle (apart from the
change in bleach cleaning solution) could have played a role in the reduction
of VRE.SP 24-3
CONTROLLING THE HEALTHCARE-ASSOCIATED SPREAD OF
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE
David K. Henderson. NIH Clinical Center, United States
This presentation addresses the burgeoning problem of antimicrobial
resistance, first attempting to place the current situation in historical
perspective, secondly underscoring the fact that we are faced currently
with several specific multiply-resistant pathogens, including Methicillin-
resistant Staphylococcus aureus, Vancoycin-resistant enterococci, and
Clostridium difficile, among others. The discussion will then focus on the
speicif problems relating to the control of Carbapenem-Resistant Entero-
bacteriaceae (CRE) in healthcare. The presentation next discusses preven-
tion interventions in historical perspective, noting the challenges
associated with the “Semmelweis Effect” and attempts to induce cultural
change. The presentation next focuses on specific MDRO outbreaks that
have occurred at the Clinical Center at the National Institutes of Health,
emphasizing the interventions employed and discussing the practical appli-
cation of whole genome sequencing to issues of relevance to healthcare
epidemiology.SP 24-4
STEWARDSHIP STRATEGIES TO CONTROL MDRO
Ursula Theuretzbacher. Center for Anti-Infective Agents, Vienna, Austria
Antimicrobial stewardship (AMS) programs aim at ensuring appropriate and
responsible use of antimicrobial drugs in order to provide optimized
treatment outcome including a reduced risk of adverse effects and
minimized risk of emergence of resistance while promoting cost-effective-
ness. In addition to the immediate effects on individual patients and health
care systems the aspect of preserving the power of antimicrobial drugs as
vital resources for future generations gains momentum. AMS is recognized as
a key component in addressing the global challenge of increasing antimi-
crobial resistance. Global strategies are needed to define “responsible use”
of antibiotics and create a global framework for AMS strategies to control
the selection pressure on pathogens. International initiatives such as DRIVE-
AB and stewardship strategies are discussed to preserve the activities of
antibiotics in an era of limited supply of new drugs.
